10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium
10x Genomics (TXG) announced the launch of the Fixed RNA Profiling Kit and Nuclei Isolation Kit on April 14, 2022. These products enhance sample preparation workflows for single cell analysis, targeting the challenges in handling fragile human tissues and frozen samples. The Fixed RNA Profiling Kit allows researchers to store samples post-collection without cryopreservation, while the Nuclei Isolation Kit simplifies the extraction of nuclei from frozen tissue, making the process more efficient. Both kits are set to ship mid-May 2022, aiming to broaden the use of single cell analysis in research.
- Launch of Fixed RNA Profiling Kit enhances flexibility in sample collection and reduces reliance on cryopreservation.
- Nuclei Isolation Kit simplifies and speeds up the process of single cell analysis from frozen tissues.
- Expected shipment of both kits in mid-May 2022 could drive sales and market adoption.
- None.
Fixed RNA Profiling Kit stabilizes human samples at collection; Nuclei Isolation Kit simplifies frozen sample analysis
PLEASANTON, Calif., April 14, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the commercial availability of two new products designed to improve sample preparation workflow and broaden the adoption of the company's leading Chromium platform for single cell analysis: Fixed RNA Profiling and Nuclei Isolation Kits. Together, these kits will enable easier single cell multiomic analysis of fragile human tissue samples and make frozen sample analysis, which is currently costly and time consuming, more accessible.
"Single cell analysis is revolutionizing biomedical research and transforming the future of health and medicine," said Ben Hindson, Co-founder and Chief Scientific Officer for 10x Genomics. "We believe the new capabilities we're announcing today will bring the future forward and help realize the expanding potential of single cell analysis by removing obstacles to larger scale, multi-site studies and enabling broader adoption of single cell methods in translational research."
Hindson continued, "These new kits are among the first of several new products planned across our Chromium, Visium and Xenium platforms this year. We're working hard to make 2022 the most exciting year of product launches in our history."
Currently, single cell researchers must intricately plan and coordinate their experiments so as to maintain cell viability of live samples, working quickly from sample collection through to processing.
"A key limiting factor of RNA sequencing is the availability of resources at the time of collection, which can occur outside normal working hours due to various reasons," said Luciano Martelotto, Ph.D., Associate Professor, Single Cell and Spatial Technologies Lab at the University of Adelaide. "The Fixed RNA Profiling kit allows fixation of cells immediately after single cell suspension preparation, making it possible to store cells for future experiments without relying on cryopreservation, which can distort the cell composition of the original sample."
The Fixed RNA Profiling Kit enables researchers to fix their tissue at the time of collection, store it, and proceed to a single cell workflow at a time and place of their choosing. The kit, which combines entirely new chemistry and chip with a formaldehyde fixation to preserve the biological state at the point of collection, enables batching of samples for maximum study flexibility. In addition, the kit provides improved sensitivity and more efficient sequencing as well as built-in sample multiplexing capabilities. With the ability to probe cell surface protein expression for multiomic studies, the Fixed RNA Profiling Kit is compatible with any human single cell suspension.
"Single cell measurements have been transformative to our understanding of human health and disease, but the research potential has been hampered by cost," said Peter Skene, Ph.D., Director of Molecular Biology & Biochemistry at the Allen Institute for Immunology. "New multiplexed technologies promise to significantly reduce the cost and boost global research. By locking the cell state, fixed cell measurements will allow unprecedented insight into drug mechanisms, including intracellular protein measurements. Taken together, the new era of single cell research will be a paradigm shift phase in translational research."
For researchers with unsequenced archival tissue, 10x Genomics developed the Nuclei Isolation Kit to unlock frozen tissues for single cell analysis, answering a major customer request. Standard methods for nuclei isolation from frozen tissue include complex, low-throughput and time-consuming protocols, expensive instruments for sorting and debris removal, and the need to optimize workflows for each tissue. The Nuclei Isolation Kit is a simple, scalable product designed to remove those barriers. With an hour of time and a benchtop centrifuge, the kit enables the generation of high quality nuclei suspensions from a wide range of frozen samples on Chromium, without any expensive instruments or complicated pipetting.
The Fixed RNA Profiling Kit is available now for pre-order, while the Nuclei Isolation Kit is expected to open for pre-order soon. Both kits are expected to begin shipping in mid-May.
In addition, earlier this month, 10x Genomics began shipping both 5' CRISPR, an extension to Single Cell Immune Profiling to make large scale, functional genomics studies quicker and easier; and ATAC v2, an update to the Single Cell ATAC-seq workflow to boost sensitivity while increasing discovery power and reducing costs.
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company's integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 3,300 research papers on discoveries ranging from oncology to immunology and neuroscience. The company's patent portfolio comprises more than 1,300 issued patents and patent applications.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product performance, configuration, capabilities and adoption. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors, including the potential impact of the COVID-19 pandemic. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.
10x Genomics uses filings with the SEC, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Media Contact:
media@10xgenomics.com
Investor Relations Contact:
investors@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-two-new-products-to-unlock-wider-range-of-samples-for-single-cell-analysis-on-chromium-301525562.html
SOURCE 10x Genomics, Inc.
FAQ
What are the new products launched by 10x Genomics on April 14, 2022?
How does the Fixed RNA Profiling Kit benefit researchers?
When are the new kits expected to start shipping?
What issue does the Nuclei Isolation Kit address?
What is the significance of single cell analysis in research?
